KRISTIN BUSSE: Open Payments
NPI 1568821429 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,307 in 108 payments from 19 companies in 2025. Trend: 2023 $1,887 · 2024 $1,488 · 2025 $2,307
Food & beverage: $2,307
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 21 | $463 |
| ABBVIE INC. | 24 | $447 |
| Janssen Biotech, Inc. | 21 | $302 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $192 |
| Ipsen Biopharmaceuticals, Inc | 3 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $120 |
| Madrigal Pharmaceuticals | 4 | $84 |
| Janssen Scientific Affairs, LLC | 1 | $83 |
| Ardelyx, Inc. | 4 | $80 |
| Celltrion USA Inc. | 4 | $72 |
Products named: TREMFYA, RINVOQ, XIFAXAN, IQIRVO, Epclusa, EOHILIA, LINZESS, REZDIFFRA.
Industry payments across NE — which companies pay providers there.
